The effect of tezepelumab in patients with allergic asthma: Results from the PATHWAY phase IIb study

被引：0
|
作者：
Corren, J. [1 ]
Colice, G. [2 ]
Salapa, K. [3 ]
Bowen, K. [4 ]
Llanos-Ackert, J. [5 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] AstraZeneca, San Francisco, CA USA
[3] AstraZeneca, Warsaw, Poland
[4] AstraZeneca, Gaithersburg, MD USA
[5] Amgen Inc, Gaithersburg, MD USA
来源：
ALLERGY | 2020年 / 75卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
1105
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [1] The effect of tezepelumab in patients with allergic and non-allergic asthma: results from the NAVIGATOR phase 3 study
    Corren, J.
    Menzies-Gow, A.
    Ambrose, C. S.
    Cook, B.
    Kmita, K.
    Colice, G.
    Llanos-Ackert, J.
    ALLERGY, 2021, 76 : 13 - 14
  • [2] Efficacy of tezepelumab in patients with evidence of severe allergic asthma: Results from the phase 3 NAVIGATOR study
    Corren, Jonathan
    Ambrose, Christopher S. S.
    Griffiths, Janet M. M.
    Hellqvist, Asa
    Lindsley, Andrew W. W.
    Llanos, Jean-Pierre
    Colice, Gene
    Menzies-Gow, Andrew
    CLINICAL AND EXPERIMENTAL ALLERGY, 2023, 53 (04): : 417 - 428
  • [3] Tezepelumab in patients with allergic and eosinophilic asthma
    Caminati, Marco
    Buhl, Roland
    Corren, Jonathan
    Hanania, Nicola A.
    Kim, Harold
    Korn, Stephanie
    Lommatzsch, Marek
    Martin, Neil
    Matucci, Andrea
    Nasser, Shuaib M.
    Pavord, Ian D.
    Domingo, Christian
    ALLERGY, 2024, 79 (05) : 1134 - 1145
  • [4] Tezepelumab Efficacy in Patients with Allergic and Non-Allergic Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study
    Corren, Jonathan
    Colice, Gene
    Salapa, Kinga
    Bowen, Karin
    Llanos-Ackert, Jean-Pierre
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2021, 147 (02) : AB157 - AB157
  • [5] Effect of Tezepelumab in Oral Corticosteroid-Dependent Patients with Severe Asthma: Results From the Phase 3 NAVIGATOR Study
    Menzies-Gow, A.
    Brightling, C. E.
    Ambrose, C. S.
    Cook, B.
    Hellgvist, A.
    Ackert, J. Llanos
    Colice, G.
    Wechsler, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [6] TEZEPELUMAB EFFICACY IN SEVERE ASTHMA BY SPECIFIC ALLERGEN SENSITIVITY: RESULTS FROM THE PATHWAY STUDY
    Corren, J.
    Ambrose, C.
    Salapa, K.
    Parnes, J.
    Colice, G.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S5 - S6
  • [7] EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA, ACCORDING TO BASELINE BODY MASS INDEX: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Ambrose, C. S.
    Colice, G.
    Salapa, K.
    Parnes, J. R.
    Corren, J.
    THORAX, 2021, 76 : A83 - A83
  • [8] Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study
    Kraft, M.
    Chupp, G. L.
    Reeh, K.
    Lindsley, A. W.
    Cook, B.
    Hunter, G.
    Ambrose, C. S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [9] THE EFFECT OF TEZEPELUMAB ON EXACERBATIONS IN PATIENTS WITH SEVERE, UNCONTROLLED ASTHMA ACCORDING TO BASELINE INHALED CORTICOSTEROID DOSE: RESULTS FROM THE PHASE 2B PATHWAY STUDY
    Corren, Jonathan
    Ambrose, Christopher
    Salapa, Kinga
    Parnes, Jane
    Colice, Gene
    CHEST, 2020, 158 (04) : 30A - 31A
  • [10] Effect of Tezepelumab on Exacerbations in Patients with Severe, Uncontrolled Asthma, According to Baseline Body Mass Index: Results from the Phase 2b PATHWAY Study
    Ambrose, Chris
    Colice, Gene
    Salapa, Kinga
    Parnes, Jane
    Corren, Jonathan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB25 - AB25
12345